Versigent initiated with a Hold at Deutsche Bank

Deutsche Bank initiated coverage of Versigent (VGNT) with a Hold rating and $35 price target The company has an “attractive, cash-generative” operating model but there is some risk to this year’s guidance, the analyst tells investors in a research note. The firm also believes the current macro environment could put pressure on Versigent’s multiple in the near term.